Recent Updates
Recently added Catalysts
AZN Positive Sentiment

insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Thursday, October 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: insitro has entered into a strategic collaboration with AstraZeneca to leverage AI in the discovery of new therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. The agreement includes an upfront payment of $40 million to insitro, with additional financial opportunities tied to the success of the research. This partnership aims to address significant unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to discover novel therapeutics for serious conditions.
  • insitro receives significant upfront funding of $40 million.
  • Potential for future financial incentives based on research success.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
1.5%
average across 15 past catalysts
Lead asset
Elecoglipron
Phase 3 · Obesity

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, an AI company unlocking causal human biology to systematically generate high-value therapeutics to treat grievous illness, today announced a worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Under the terms of the agreement, insitro will receive $40 million upfront and is eligible for up to approxim

Frequently Asked Questions

What is the focus of the insitro and AstraZeneca collaboration?

The collaboration focuses on discovering novel therapeutics for MASH and cardiomyopathies.

How much funding did insitro receive from AstraZeneca?

insitro received $40 million upfront from AstraZeneca.

What technology is insitro utilizing in this partnership?

insitro is using AI to unlock causal human biology for drug discovery.

What are the potential financial benefits for insitro?

insitro is eligible for additional financial incentives based on research success.

ShareAdd on Google
Tags: AZN insitro AstraZeneca MASH cardiomyopathies therapeutics
Last updated: Oct 15, 2026

Biotech snapshot

Lead asset
ElecoglipronPhase 3
Obesity →

Catalyst track record

+8%
best trade around AZN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for AZN.

See every catalyst's timing & PoA →